Perifosine (KRX-0401)

For research use only.

Catalog No.S1037 Synonyms: NSC639966, D21266

145 publications

Perifosine (KRX-0401) Chemical Structure

CAS No. 157716-52-4

Perifosine (KRX-0401, NSC639966, D21266) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 470 In stock
USD 870 In stock
USD 1970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Perifosine (KRX-0401) has been cited by 145 publications

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description Perifosine (KRX-0401, NSC639966, D21266) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.
Targets
Akt [1]
(MM.1S cells)
4.7 μM
In vitro

Perifosine develops anti-proliferative properties with IC50 of 0.6-8.9 μM in immortalized keratinocytes (HaCaT), and head and neck squamous carcinoma cells. [1] Perifosine strongly reduces phosphorylation levels of Akt and extracellular signal-regulated kinase (Erk) 1/2, induces cell cycle arrest in G1 and G2, and causes dose-dependent growth inhibition of mouse glial progenitors. [2] Perifosine (10 μM) completely inhibits the phosphorylation of Akt in MM.1S cells. [3] A recent study demonstrates Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylation. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
T24 BC  NXTKeZBKTnWwY4Tpc44hSXO|YYm= MmL6NE42NzFxMj61JO69VQ>? M4ThUlMhcA>? NFjlSJlz\WS3Y3XzJJRp\SCkYYPhcEBESiC2eYLvd4lv\SCyaH;zdIhwenmuYYTpc44hdGW4ZXzzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NUnodoFNOjZyOUe4O|M>
T24 BC  M3\Z[WNmdGxiVnnhZoltcXS7IFHzd4F6 MX:wMlUwOS9{LkWg{txO MnXPNlQhcA>? NYjMOopO\W6qYX7j[ZMhe2:{YX\lcoljNWmwZIXj[YQh[2WubDD2bYFjcWyrdImg[IVkemWjc3W= NFPJOoYzPjB7N{i3Ny=>
T24 BC  NHLtN5JCeG:ydH;zbZMhSXO|c3H5 NVzRTmhpOi53IN88US=> Mo\VNlQhcA>? M{PRe5NmdnOrdHn6[ZMhSkNiY3XscJMhfG9ic3;yZYZmdmmkLXnu[JVk\WRiYYDvdJRwfGmlwrC= NWXsfItoOjZyOUe4O|M>
HepG2 NXPvfGRYTnWwY4Tpc44hSXO|YYm= NEDoO|AzOMLizszN M{H6[|I1yqCq NXnrUIJHeHKxZIXj[ZMh[W5iaX70[Y5{\SCleYTvdIxie22rYzD2ZYN2d2yrenH0bY9vKGOxcoLld5BwdmSrbnegeI8h[SCwb4ThZoxmKGSrbHH0ZZRqd25ib3[geIhmKEWUIHPpd5Rmem6| M{XEPFI2QTN2MkOy
U-87 MG  NVPGRodXTnWwY4Tpc44hSXO|YYm= NYPabIxlOjEEoN88US=> NWLTXHgyOjUEoHi= NHLZUJBqdmO{ZXHz[ZMh\G:3YnzlMY1mdWK{YX7lJIJwfW6mIIP0dpVkfHW{ZYO= M2L6elI2QTN2MkOy
HepG2 MYrGeY5kfGmxbjDBd5NigQ>? NH;KVFUzOMLizszN MXO2M|I1KGh? MlvWbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZiTFOzMWlKKGOxdILlZZRm\CC5aYToJGNS NIjId|czPTl|NEKzNi=>
U-87 MG  M1jYdGZ2dmO2aX;uJGF{e2G7 NHPZZXgzOMLizszN NFzSPIs3NzJ2IHi= M3HGTolv[3KnYYPld{B1cGVibHX2[Yx{KG:oIFzDN{1KUSClb4Ty[YF1\WRid3n0bEBEWQ>? M1X0WFI2QTN2MkOy
HepG2 NXS0WmMzTnWwY4Tpc44hSXO|YYm= MYOyNOKh|ryP NV;GO3MxPi9{NDDo MYrk[YNz\WG|ZYOgUGM{NUmLIHTl[5Ji\GG2aX;uxsBnem:vIE[gbC=> NWD4NYFlOjV7M{SyN|I>
U-87 MG  NVW5[|U4TnWwY4Tpc44hSXO|YYm= MYGyNOKh|ryP MoezOk8zPCCq NYG0c5V5cW6lcnXhd4V{KHSqZTDheZRweGijZ3njJIZtfXhiIHH0JFYhcCC5aHns[UBqdmirYnn0d{B1cGm|IH\seZgh[XRiMkTo MXOyOVk{PDJ|Mh?=
HepG2 NF;Ic4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELSfI8zOC92MDFOwG0> MWiyOE81QCCq NFHyUGJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NVO1SIxuOjV7M{SyN|I>
U-87 MG  Mmq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnDNlAwPDBizszN MojuNlQwPDhiaB?= NXzLdog3cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= M134T|I2QTN2MkOy
A549 M4jJdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HoW|AvOy1zMDFOwG0> NVTROlVOOjRxN{KgbC=> MUHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NY[xPZRTOjV4OUe4PVk>
H460 NHiyRmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLWbJgxNjNvMUCg{txO MVmyOE84OiCq NYX6bVVjcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MYqyOVY6Pzh7OR?=
A549 MYrBdI9xfG:|aYOgRZN{e2G7 NU\UblJYOS9|IN88US=> Mnu3OFghcA>? MnfpbY5lfWOnczDhdI9xfG:|aYO= MWmyOVY6Pzh7OR?=
H460 M13rNGFxd3C2b4Ppd{BCe3O|YYm= M{DE[|EwOyEQvF2= NUTMdpJGPDhiaB?= MnrWbY5lfWOnczDhdI9xfG:|aYO= NWnaXopxOjV4OUe4PVk>
A549 M{nJPGZ2dmO2aX;uJGF{e2G7 M3nVOFMh|ryP NEDIXZE5KGh? NFXifmJjdG:la4OgRWtVKGGldHn2ZZRqd25? MkDUNlU3QTd6OUm=
H460 NWex[otjTnWwY4Tpc44hSXO|YYm= NITV[pk{KM7:TR?= M4rDSlghcA>? M1LTeYJtd2OtczDBT3Qh[WO2aY\heIlwdg>? NXHWeWpWOjV4OUe4PVk>
A549 NXHPb3FETnWwY4Tpc44hSXO|YYm= MojhN{DPxE1? NWDpbJZ5QCCq Mon6Zoxw[2u|IH3UU3JEOSxiYX7kJGVTUy2PQWDLJIFkfGm4YYTpc44h[2:vYnnu[YQhf2m2aDDNSWsuOTZ{ NVnyPVd6OjV4OUe4PVk>
H460 NF60RmNHfW6ldHnvckBCe3OjeR?= MnH3N{DPxE1? NXLGXmRGQCCq M3rzfIJtd2OtczDtWG9TSzFuIHHu[EBGWktvTVHQT{Bi[3SrdnH0bY9vKGOxbXLpcoVlKHerdHigUWVMNTF4Mh?= MoG1NlU3QTd6OUm=
RMG1 MUnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NXfNeHBmOS1|MDFOwG0> MojKO|IhcA>? MkX2[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M{Dl[FI2PTF7MUS4
RMG2 MXjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M2GyWVEuOzBizszN NYjZSnRXPzJiaB?= M4rPWIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= Mm\rNlU2OTlzNEi=
KOC7C NH\QcJhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NVzENHloOS1|MDFOwG0> M{fVN|czKGh? MkPm[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M3foRVI2PTF7MUS4
HAC2 MlvnR4VtdCCYaXHibYxqfHliQYPzZZk> MYmxMVMxKM7:TR?= M4rwe|czKGh? M2XpTYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NHKyc3AzPTVzOUG0PC=>
RMG2 MVvD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NHTrfFMyNTNyIN88US=> NUfOVZFiPDhiaB?= MWDk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NEm5NlkzPTVzOUG0PC=>
OVISE NWfnZmoxS2WubDDWbYFjcWyrdImgRZN{[Xl? NWToSZc6OS1|MDFOwG0> MUK0PEBp Mon2[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ Ml;aNlU2OTlzNEi=
SKOV3 NFW5VWRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MXuxMVMxKM7:TR?= MoPUOFghcA>? NYL2NGE3\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy MVGyOVUyQTF2OB?=
A2780 M1vXZ2NmdGxiVnnhZoltcXS7IFHzd4F6 Mn6wNU0{OCEQvF2= Mnv5OFghcA>? MX7k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MUGyOVUyQTF2OB?=
RMG1 NUnqWY03SXCxcITvd4l{KEG|c4PhfS=> NXPqZVQ2OzBizszN M2jmNlI1KGh? MV;pcoR2[2W|IHHwc5B1d3Orcx?= MkDiNlU2OTlzNEi=
RMG2 MXjBdI9xfG:|aYOgRZN{e2G7 M3zme|MxKM7:TR?= Ml\TNlQhcA>? NUSyeXlXcW6mdXPld{BieG:ydH;zbZM> MojoNlU2OTlzNEi=
HCC1806 M3fFeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{T2elAuOTBizszN MkTJOFghcA>? MV;FR|UxRTJwOEVihKnDueLCiUCuNFch|ryP Mn;1NlUzQTN3N{[=
MDA-MB-231  NIXnNoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHrSXhxOC1zMDFOwG0> NXX0T4pWPDhiaB?= MkKySWM2OD1zLkGz5qCKyrIkgJmwMlA4KM7:TR?= NWG0eWtZOjV{OUO1O|Y>
GL-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLvdW0xNjIkgKOxNFDjiIoQvF2= MnTBOFghcA>? M1;s[WlEPTB;OT65NUDPxE1? M{Dp[lI1QDhzNUC4
CLBL-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3i3d|AvOeLCk{GwNQKBkc7:TR?= Mm[4OFghcA>? NYLXUnd3UUN3ME2zN{4xKM7:TR?= MYmyOFg5OTVyOB?=
UL-1 M2XOVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml:3NE4y6oDVMUCw5qCK|ryP MoLPOFghcA>? M1fqVGlEPTB;Nz6wNUDPxE1? NGPpcXUzPDh6MUWwPC=>
Ema MkS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfENE4y6oDVMUCw5qCK|ryP NHXIOIg1QCCq NYTLe|U6UUN3ME21PE44KM7:TR?= Mnn0NlQ5QDF3MEi=
PANC-1 M4jYPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDZbIVpOC1{NTFOwG0> NEjidpo4OiCq MVjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MlXmNlQ2OTl5NUG=
MIA MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorNNE0zPSEQvF2= NH\QdYY4OiCq Mlj2bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MYeyOFUyQTd3MR?=
AsPC-1 NH;jd49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MViwMVI2KM7:TR?= M{PJNlczKGh? M{X1WolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MUiyOFUyQTd3MR?=
PANC-1 M1PIRmZ2dmO2aX;uJGF{e2G7 NVHsOZZOOC53IN88US=> NWna[XlCOjRiaB?= M4fKU4lvcGmkaYTzJGFsfCxiU{\LNUwh[W6mIFXyb|EwOiCyaH;zdIhwenmuYYTpc47DqA>? NEPpeGgzPDVzOUe1NS=>
MIA NHrQbpZHfW6ldHnvckBCe3OjeR?= NHr0[FMxNjVizszN NIPyZmIzPCCq MX3pcohq[mm2czDBb5QtKFN4S{GsJIFv\CCHcnuxM|IheGixc4Doc5J6dGG2aX;uxsA> NIDzd4IzPDVzOUe1NS=>
AsPC-1 NW\Cc5M4TnWwY4Tpc44hSXO|YYm= MkPNNE42KM7:TR?= MWeyOEBp NUDCbllIcW6qaXLpeJMhSWu2LDDTOmsyNCCjbnSgSZJsOS9{IIDoc5NxcG:{eXzheIlwdsLi M4nMfFI1PTF7N{Wx
U87MG M4nafWNmdGxiVnnhZoltcXS7IFHzd4F6 NVSxTIpXOC1{NTFOwG0> M2K5WFI1NTl4IHi= M4r4ZYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> NID0V|IzPDB4NUWyNi=>
SGC7901  M{Plc2Z2dmO2aX;uJGF{e2G7 NF33e5cxNjd3L{GwxsDPxE1? M1rIUVQ5KGh? NXS4N2JI\GWlcnXhd4V{KHBvQXv0JEhU\XJiNEezLUwheC2JU1uz{tIhMFOncjC5LUwh[W6mIFOtUXlEKGyndnXsd:Kh M3:xO|I{QTF{MkS2
MGC803  MlnPSpVv[3Srb36gRZN{[Xl? M{Xwe|AvPzVxMUFCpO69VQ>? MnzLOFjDqGh? NHzLN2Zl\WO{ZXHz[ZMheC2Da4SgLHNmeiB2N{OpMEBxNUeVS{ROtkApW2W{IEmpMEBidmRiQz3NXWMhdGW4ZXzzxsA> NHvmWJUzOzlzMkK0Oi=>
TykNu MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLpZZYxUUN3ME2zMlUh|ryP NX7ZTm0xOjN6N{ewNVI>
TykNuR NVz4PWNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rUe2lEPTB;NT61JO69VQ>? M{nQUVI{QDd5MEGy
M41 NXjvdGlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\TTWM2OD1{ND63JO69VQ>? NHS2[VIzOzh5N{CxNi=>
M41R MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTF7Lkig{txO M3zwNFI{QDd5MEGy
OVCAR8 NGKzdVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HGOWlEPTB;M{GuNUDPxE1? M331d|I{QDd5MEGy
HeyA8 M4DkTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XyN2lEPTB;MkSuN{DPxE1? M4LURlI{QDd5MEGy
A2780CP NEC2c2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fPPWlEPTB;Nz62JO69VQ>? MnvFNlM5PzdyMUK=
OVCAR5 M{\zOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTZwNzFOwG0> MYmyN|g4PzBzMh?=
A2780S NHHjUGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;TTIVKSzVyPUG0MlUh|ryP Mly4NlM5PzdyMUK=
MCAS M3LJR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvDTWM2OD1zMj61JO69VQ>? NEXyPWIzOzh5N{CxNi=>
NCI-H727 MojmR4VtdCCYaXHibYxqfHliQYPzZZk> MYWwMVExOCEQvF2= NYDZOIVNOjRxN{KgbC=> NG\OSYpl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> M3TVflIzPDl7NEO3
GOT1 NXnpfo04S2WubDDWbYFjcWyrdImgRZN{[Xl? Mlr4NE0yODBizszN NVfGbVJ4OjRxN{KgbC=> Mmr6[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy Ml7LNlI1QTl2M{e=
BON1 MoP0R4VtdCCYaXHibYxqfHliQYPzZZk> NFjYeZIxNTFyMDFOwG0> NVfBd4ZoOjRxN{KgbC=> M2fE[4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> Mkj5NlI1QTl2M{e=
BON1 NF;6fWVCeG:ydH;zbZMhSXO|c3H5 MnG4NE0yOCEQvF2= NIHTVmszPCCq Mn\GbY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= MWSyNlQ6QTR|Nx?=
BON1 NYHRN|BETnWwY4Tpc44hSXO|YYm= MljVO{42NzFyIN88US=> NVPrO5ltQCCq NYHsfVFn\GWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKHSqZTDhcpRqNWGyb4D0c5Rq[yCycn;0[YlveyCEQ1yyJIFv\CCEY3ytXGw> MYWyNlQ6QTR|Nx?=
Kasumi-1 MnLDR4VtdCCYaXHibYxqfHliQYPzZZk> M1vHSFAuOjBizszN MljoNlQwPDhiaB?= Mmfq[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy Mn31NlI1ODd{Mki=
HL-60 MX;D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NVPzXGE3OC1{MDFOwG0> MoLxNlQwPDhiaB?= NVnURmhK\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGKxdHig[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz MYKyNlQxPzJ{OB?=
Kasumi-1 NFf4XodCeG:ydH;zbZMhSXO|c3H5 NVezNIZwOTBizszN Ml71NlQhcA>? NF3PZpFqdmS3Y3XzJIFxd3C2b4Ppdy=> MmnqNlI1ODd{Mki=
HL-60 MmS1RZBweHSxc3nzJGF{e3OjeR?= MXyxNEDPxE1? NUjlXXhzOjRiaB?= NXrrdolzcW6mdXPld{BieG:ydH;zbZM> M{PlbFIzPDB5MkK4
Kasumi-1 MkHVSpVv[3Srb36gRZN{[Xl? M3LCVlIvPS93L{GwJO69VQ>? NX;sVXdiOjRiaB?= NWHKb2U{\GWlcnXhd4V{KEGtdDDhcoQheC2Da4SgcIV3\Wy|wrDkc5NmNWSncHXu[IVvfGy7 MYWyNlQxPzJ{OB?=
HL-60 MX;GeY5kfGmxbjDBd5NigQ>? NGDnS|AzNjVxNT:xNEDPxE1? NWD4bVdnOjRiaB?= M2fi[oRm[3KnYYPld{BCc3RiYX7kJJAuSWu2IHzleoVte8LiZH;z[U1l\XCnbnTlcpRtgQ>? NYnPSXd4OjJ2MEeyNlg>
Kasumi-1 M3n2TGZ2dmO2aX;uJGF{e2G7 MVOyMlUwPS9zMDFOwG0> NWfzTodDOjRiaB?= MV\pcoR2[2W|IITo[UBxcG:|cHjvdplt[XSrb36gc4YhUk6NMT:yJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy MmH1NlI1ODd{Mki=
HL-60 NGjqfI5HfW6ldHnvckBCe3OjeR?= M2TkdVIvPS93L{GwJO69VQ>? MnjJNlQhcA>? M4TxU4lv\HWlZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCMTluxM|IhcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M{\YPVIzPDB5MkK4
K562 NYnOelJDTnWwY4Tpc44hSXO|YYm= M2nTblIxKM7:TR?= Mn:4OFghcA>? MojSbY5lfWOnczDheZRweGijZ4pCpC=> M3[3b|IzPDB5MkK4
OCUT1 MorOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1r1ZlAvOS1|IN88US=> NV;PNoZNPSCm MonibY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MXiyNlA6ODJ5MR?=
K1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVX3XJpLOC5zLUOg{txO M2rOO|Uh\A>? MYTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MmH0NlIxQTB{N{G=
OCUT1 NFXxSJdHfW6ldHnvckBCe3OjeR?= MV:zJO69dQ>? NVLXXXBwOjRiaB?= MnLtZ4F2e2W|IHGg[JJidWG2aXOgbY5kemWjc3WgbY4hTzJxTTDwbIF{\Q>? M3O5TFIzODlyMkex
CaOV3 Mly0R4VtdCCYaXHibYxqfHliQYPzZZk> MV2xM|UwOTBizszN M3[5U|Q5KGh? NWLidnpD\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXyJINwfHKnYYTl[EB4cXSqIIDhZ4xqfGG6ZXy= MkntNlE4PzVyNUS=
SKOV3 M1HCZWN6fG:2b4jpZ4l1gSCDc4PhfS=> MVu1JO69VQ>? MX60PEBp NH[2d|ZmdmijbnPld{Bx[WOuaYThfIVtKGmwZIXj[YQhd3[jcnnhckBk[W6lZYKgZ4VtdCCmZXH0bOKh MViyNVc4PTB3NB?=
A2780 MXPDfZRwfG:6aXPpeJkhSXO|YYm= MVS1JO69VQ>? NV31NIxNPDhiaB?= M1jYXYVvcGGwY3XzJJBi[2yrdHH4[YwhcW6mdXPl[EBwfmG{aXHuJINidmOncjDj[YxtKGSnYYToxsA> NFrLT3AzOTd5NUC1OC=>
HT-29  MWfDfZRwfG:6aXPpeJkhSXO|YYm= M2T2[lUh|ryP M1;UN|Q5KGh? NWTQ[VBV\W6qYX7j[ZMheGGlbHn0ZZhmdCCrbnT1Z4VlKG:4YYLpZY4h[2GwY3XyJINmdGxiZHXheIjDqA>? M2nXcFIyPzd3MEW0
A498 NH3SdIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojJNE01OCEQvF2= MonRO|IhcA>? NUH4S25zcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NILnO2QzOTZ2NEC1NC=>
CAKI-1 NWXPdXpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PpVVAuPDBizszN MW[3NkBp Ml3XTWM2OH5zMDFOwG0> NWDVd4lPOjF4NESwOVA>
769-P M2DiUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXKwMVQxKM7:TR?= MofHO|IhcA>? MYjJR|UxhjVvMUCg{txO M{n0XFIyPjR2MEWw
786-0 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYOwMVQxKM7:TR?= MmfQO|IhcA>? NXXKNWlyUUN3MI61JO69VQ>? MlW4NlE3PDRyNUC=
786-O MojaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorRNE0zOCEQvF2= MWK3NkBp M4LiOYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NIDYWZMzOTZ2NEC1NC=>
CAKI-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmS5NE0zOCEQvF2= MXu3NkBp MkLPbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M{\QR|IyPjR2MEWw
769-P MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWiwMVIxKM7:TR?= M4jYVVczKGh? MYrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NGXWd2YzOTZ2NEC1NC=>
A498 MnTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUSwMVIxKM7:TR?= NFexc2I4OiCq M1TnWIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MorRNlE3PDRyNUC=
CWR22RV1 NUTwNG5US2WubDDWbYFjcWyrdImgRZN{[Xl? NWXUdZVxOTBizszN NHniOpAzPCCq MlPZbY5kemWjc3XzJJNmdnOrdHn2bZR6KG:oIHj1cYFvKEOZUkKyVnYyKGOnbHzzJJRwKHKjZHnheIlwdg>? MYmyNVQ6PjJ5Mx?=
CWR22RV1 M3XqZ2Fxd3C2b4Ppd{BCe3O|YYm= MVGxNEDPxE1? Mnj3NlQhcA>? NE\zeXlmdmijbnPld{Bz[WSrYYTpc44hcW6mdXPl[EBieG:ydH;zbZM> NH6yXpYzOTR7NkK3Ny=>
CWR22RV1 MlvHSpVv[3Srb36gRZN{[Xl? NFrWTm02KM7:TR?= M{nzelI1KGh? NVjIXZloemWmdXPl[EBxcG:|cHjvdplt[XSrb36gc4YhSWu2IIPp[45q\mmlYX70cJk> MYKyNVQ6PjJ5Mx?=
HepG2  M3vpXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnkO482NzFyL{KwM|QxKM7:TR?= MmjDNlQwPDhxN{KgbC=> MlSwbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NFTid2szODh2MkSyOS=>
Bel-7402 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LMVlUwOTBxMkCvOFAh|ryP Mn;6NlQwPDhxN{KgbC=> Ml3zbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MX[yNFg1OjR{NR?=
HepG2  Moi4SpVv[3Srb36gRZN{[Xl? NYfTSlQ2PS9zMD:yNEDPxE1? NInR[mQzPCCq MnvVdoV{fWy2czDpckB1cGViYXPjeY12dGG2aX;uJI9nKGOnbHygcpVu[mW{IHnuJJRp\SCJMj;NJJBp[XOn MlezNlA5PDJ2MkW=
Bel-7402 NIXz[IRHfW6ldHnvckBCe3OjeR?= MWO1M|ExNzJyIN88US=> MXOyOEBp MnjSdoV{fWy2czDpckB1cGViYXPjeY12dGG2aX;uJI9nKGOnbHygcpVu[mW{IHnuJJRp\SCJMj;NJJBp[XOn NFn3TWYzODh2MkSyOS=>
HepG2  MVvBdI9xfG:|aYOgRZN{e2G7 MlTiOU8yOC9{MDFOwG0> NVfVRpo3OjRxNEigbC=> M1P0Xolv\HWlZYOgZZBweHSxc3nzJIF1KHSqZTDsc45oNXSrbXWg[Zhxd3O3cnW= MXuyNFg1OjR{NR?=
Bel-7402 MmHlRZBweHSxc3nzJGF{e3OjeR?= NHfIOFM2NzFyL{KwJO69VQ>? NFv3TmwzPC92ODDo NGDDOlVqdmS3Y3XzJIFxd3C2b4Ppd{BifCC2aHWgcI9v\y22aX3lJIV5eG:|dYLl MXSyNFg1OjR{NR?=
OAW-42 M4jzXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUiwMVQxKM7:TR?= MXi3NuKhcA>? NE\zSmVKSzVyfkGwJO69VSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= M4f4RlIxPDB3Mkm2
PA-1  MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrMNE01OCEQvF2= NV;IXVBbPzMEoHi= M4rqUmlEPTC-MkWg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NFe5SIgzODRyNUK5Oi=>
SKOV3  NH;5S21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{S2XFAuPDBizszN NIX2U4U4OsLiaB?= MlrjTWM2OH5|MDFOwG0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MWmyNFQxPTJ7Nh?=
A2780 Mn:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\iW|AuOjBizszN MXq0PE84OiCq NWrXVow2UUN3MNMgQeKhO8Lizszt NH\5UGkzODRyNUK5Oi=>
A2780cis  MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYSwMVIxKM7:TR?= MW[0PE84OiCq Mn;0TWM2OMLiPdMgOuKh|ryv NU\jNo5JOjB2MEWyPVY>
SKW6.4 NU[xN|RPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVGyMVExyqEQvF2= NX7PWnR2PDkEoHi= NVnyenVmcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NVfSNI45OjBzM{C5OlA>
MAVER MlzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zMblIuOTEEoN88US=> MknsOFjDqGh? Ml\obY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MojONlAyOzB7NkC=
BJAB MlrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDS[pYzNTFywrFOwG0> NVfyV|RDPDkEoHi= NEnnNGZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M3;nbFIxOTNyOU[w
OCI NFLIVopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV:3VoVoOi1zMNMg{txO M2DsVFQ5yqCq MUDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MWKyNFE{ODl4MB?=
MOLM M3r6bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4L2dVIuOTEEoN88US=> MVi0POKhcA>? MYPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NGPwVZozODF|MEm2NC=>
HL-60 NVTLbFZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWG4c|M6Oi1zMNMg{txO MmXjOFjDqGh? MUPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> Mo\lNlAyOzB7NkC=
SKW6.4 NGTWeIRCeG:ydH;zbZMhSXO|c3H5 MXexNOKh|ryP NYXa[FlYOjRxNEigbC=> NHyxPZdqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nLXTldIVv\GWwdHz5 Mn65NlAyOzB7NkC=
MAVER NW[4dW1GSXCxcITvd4l{KEG|c4PhfS=> MVixNOKh|ryP MmHlNlQwPDhiaB?= MXfpcoR2[2W|IHHwc5B1d3OrczD0bY1mNWSncHXu[IVvfGy7 NXrPOnlDOjBzM{C5OlA>
BJAB NEW3W5dCeG:ydH;zbZMhSXO|c3H5 MVGxNOKh|ryP NIHXPVMzPC92ODDo MVnpcoR2[2W|IHHwc5B1d3OrczD0bY1mNWSncHXu[IVvfGy7 MmjBNlAyOzB7NkC=
OCI NGTzSWdCeG:ydH;zbZMhSXO|c3H5 NXHocnUxOTEEoN88US=> NWLtV41xOjRxNEigbC=> M37YdYlv\HWlZYOgZZBweHSxc3nzJJRqdWVvZHXw[Y5l\W62bIm= M2XjfVIxOTNyOU[w
MOLM NFu0T5pCeG:ydH;zbZMhSXO|c3H5 MmP6NVDDqM7:TR?= NGOxVmczPC92ODDo NHLvXY1qdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nLXTldIVv\GWwdHz5 NVH1[ZBlOjBzM{C5OlA>
HL-60 NHrIXnpCeG:ydH;zbZMhSXO|c3H5 M3noUFExyqEQvF2= NVrxRpgzOjRxNEigbC=> NFjCdlFqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nLXTldIVv\GWwdHz5 NVfI[mg{OjBzM{C5OlA>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT / AKT / p-S6K1 / S6K1 ; 

PubMed: 25519148     


The effect of perifosine on AKT-mTOR activation in vitro. RMG1 and RMG2 cells were treated with 0, 3, 10, 30 or 50 μM perifosine for 6 h in the presence of 10% FBS. Cells were harvested, and equivalent amounts (30 μg) of protein were subjected to SDS-PAGE and blotted with anti-phospho-AKT (Ser473), anti-AKT, anti-phospho-S6K1 (Thr389), anti-S6K1, or anti-β-actin antibodies.

PARP; 

PubMed: 25519148     


Perifosine induces apoptosis. RMG1 and RMG2 cells were treated with or without 30 μM perifosine for 24 h. Cells were harvested, and the effect of perifosine was evaluated by western blotting

p-mTOR / mTOR / Raptor / Rictor / p-p70S6K / p70S6K / p-4EBP1 / 4EBP1 / c-Myc / Cyclin D1; 

PubMed: 19920197     


The indicated cell lines were treated with the given concentrations of perifosine (PRFS) for 8 h.

p-PDK1 / p-GSK3α/β / p-S6R ; 

PubMed: 17761832     


BCWM.1 cells were cultured with perifosine for 6 hours with doses that ranged from 2 to 20 μM. Whole cell lysates were subjecting to Western blotting using anti–p-Akt ser473, -Akt, –p-PDK1, –p-GSK3α/β, –p-S6R, and α-tubulin antibodies.

25519148 19920197 17761832
Growth inhibition assay
Cell viability; 

PubMed: 28332584     


Cell survival measured by MTT assay and IC50 of perifosine in a panel of eleven human cancer cells.

28332584
In vivo Perifosine combining with temozolomide reduces tumor proliferation (a PDGF-driven gliomagenesis) in vivo. The results indicate that Perifosine is an effective drug in gliomas in which Akt and Ras-Erk 1/2 pathways are frequently activated, and may be new candidate for glima treatment in the clinic. [2] Both oral daily and weekly administration of Perifosine significantly reduce human MM tumor growth and increase survival, compared with control animals treated with PBS vehicle only. [3] Perifosine induces thrombocytosis and leukocytosis and increases myelopoiesis in murine marrow and spleen, whereas it causes apoptosis in myeloma xenografts. [5]

Protocol

Kinase Assay:[3]
- Collapse

Akt kinase assay:

MM.1S cells are cultured in the presence or absence of perifosine (5 μM, 6 hours) and then stimulated with IL-6 (20 ng/mL, 10 minutes). In vitro akt kinase assay is then carried out using the Akt Kinase Assay Kit.
Cell Research:[2]
- Collapse
  • Cell lines: Human glioma cell lines
  • Concentrations: 0, 15, 30 and 45 μM
  • Incubation Time: 48 hours
  • Method: Cells are incubated in the medium with 10% FCS for 48 hours with indicated concentration of Periosine. Cell viability is determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. (Cell Proliferation Kit I; Roche). The absorbance at 590 nm is recorded using the 96-well plate reader.
    (Only for Reference)
Animal Research:[3]
- Collapse
  • Animal Models: MM.1S MM cells are inoculated subcutaneously in the right flank of Beige-nude-xid (BNX) mice (5 to 6 weeks old).
  • Dosages: 250 mg/kg/wk or 36 mg/kg/d
  • Administration: Oral gavage
    (Only for Reference)

Solubility (25°C)

In vitro Water 8 mg/mL (17.32 mM)
DMSO Insoluble
Ethanol '15 mg/mL
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
water
For best results, use promptly after mixing.
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 461.66
Formula

C25H52NO4P

CAS No. 157716-52-4
Storage powder
in solvent
Synonyms NSC639966, D21266
Smiles CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](CC1)(C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01224730 Completed Drug: perifosine Cancer AEterna Zentaris January 24 2012 Phase 1
NCT01049841 Completed Drug: perifosine + temsirolimus Pediatric Solid Tumors Memorial Sloan Kettering Cancer Center|University of Wisconsin Madison|Duke University|NATL COMP CA NETWORK|Pfizer|AEterna Zentaris January 2010 Phase 1
NCT01048580 Completed Drug: Perifosine|Drug: Capecitabine Colon Cancer AEterna Zentaris|SCRI Development Innovations LLC October 2009 Phase 1
NCT00776867 Completed Drug: perifosine Solid Tumors Memorial Sloan Kettering Cancer Center|University of Wisconsin Madison|Duke University|AEterna Zentaris October 2008 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Related Akt Products

Tags: buy Perifosine (KRX-0401) | Perifosine (KRX-0401) supplier | purchase Perifosine (KRX-0401) | Perifosine (KRX-0401) cost | Perifosine (KRX-0401) manufacturer | order Perifosine (KRX-0401) | Perifosine (KRX-0401) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID